
21 Feb 2024
Shield Therapeutics - FY 2023 TU; total revenues in line but Accrufer scrip revi
Total reported revenues and other income were $17.5m (our forecast $16m) in 2023 vs $5.5m in 2022. The composition of that revenue was different to our expectations such that Accrufer US revenues of $11.6m compared with $3.6m in 2022 but came in below our estimate of $13.6m. In the release, the company has noted that the methodology used by the third-party data provider for US Accrufer scrips has resulted in an overstatement for 2023. Revised figures for 2023 have been given showing 77,000 total ....

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Shield Therapeutics - FY 2023 TU; total revenues in line but Accrufer scrip revi
Shield Therapeutics Plc (STX:LON) | 3.6 0 10.9% | Mkt Cap: 37.0m
- Published:
21 Feb 2024 -
Author:
Chris Donnellan | Stuart Harris -
Pages:
5 -
Total reported revenues and other income were $17.5m (our forecast $16m) in 2023 vs $5.5m in 2022. The composition of that revenue was different to our expectations such that Accrufer US revenues of $11.6m compared with $3.6m in 2022 but came in below our estimate of $13.6m. In the release, the company has noted that the methodology used by the third-party data provider for US Accrufer scrips has resulted in an overstatement for 2023. Revised figures for 2023 have been given showing 77,000 total ....